4//SEC Filing
Beetham Thomas W. 4
Accession 0001179110-21-001370
CIK 0001730430other
Filed
Feb 4, 7:00 PM ET
Accepted
Feb 5, 6:55 PM ET
Size
8.8 KB
Accession
0001179110-21-001370
Insider Transaction Report
Form 4
Beetham Thomas W.
Chief Legal Officer10% Owner
Transactions
- Conversion
Class A Common Shares
2021-02-03+300,000→ 300,000 total - Sale
Class A Common Shares
2021-02-03$22.09/sh−2,477$54,717→ 297,523 total - Conversion
Class B Common Shares
2021-02-03−300,000→ 114,157 total→ Class A Common Shares (300,000 underlying)
Footnotes (3)
- [F1]Each Class B Common Share is convertible at any time at the election of the holder into one Class A Common Share or one Class B1 Common Share and will automatically convert into Class A Common Shares upon transfer to an unaffiliated party.
- [F2]The transactions reported in this From 4 were effected pursuant to a Rule 10b5-1 plan executed by the reporting person on June 19, 2020.
- [F3]This transaction was executed in multiple trades through a broker-dealer at prices ranging from $22.05 to $22.18. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
Documents
Issuer
Kiniksa Pharmaceuticals, Ltd.
CIK 0001730430
Entity typeother
Related Parties
1- filerCIK 0001741382
Filing Metadata
- Form type
- 4
- Filed
- Feb 4, 7:00 PM ET
- Accepted
- Feb 5, 6:55 PM ET
- Size
- 8.8 KB